Titlebook: Complement Therapeutics; John D. Lambris,V. Michael Holers,Daniel Ricklin Book 2013 Springer Science+Business Media New York 2013 infectio

到來(lái)

書目名稱Complement Therapeutics影響因子(影響力)




書目名稱Complement Therapeutics影響因子(影響力)學(xué)科排名




書目名稱Complement Therapeutics網(wǎng)絡(luò)公開度




書目名稱Complement Therapeutics網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Complement Therapeutics被引頻次




書目名稱Complement Therapeutics被引頻次學(xué)科排名




書目名稱Complement Therapeutics年度引用




書目名稱Complement Therapeutics年度引用學(xué)科排名




書目名稱Complement Therapeutics讀者反饋




書目名稱Complement Therapeutics讀者反饋學(xué)科排名

種屬關(guān)系

北極熊

鉤針織物

flaggy

https://doi.org/10.1057/9780230349414ex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The bind

爭(zhēng)吵

Captivating Quanzhou Specialties,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1

爭(zhēng)吵

Culpable

Contend

Janine O. Ilagan,Melissa S. Juricand (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove

惰性氣體

Klaus B?hmer,Günter Meinardus,Walter SchemppPNH was an appropriate medical condition to develop and to investigate therapeutical complement inhibitors. Indeed, the first complement inhibitor eculizumab, a humanized anti-C5 monoclonal antibody, has been proven safe and effective for the treatment of PNH patients. Chronic treatment with eculizu